2 insiders bought €39k of shares over the last 90 days, the latest by 정준일, filed 09 Nov 2026.
Cluster: 2 buyers in 30 daysMYUNGMOON Pharm co.,Ltd: what insiders have been doing
Every trade that managers of MYUNGMOON Pharm co.,Ltd disclose to DART (FSS) is tracked on this page. The company sits in the Health Care sector. The last twelve months, up to 9 November 2026, brought 32 filings signed by 12 insiders.
Open-market activity splits into 30 purchases totalling €12k and 1 sale; 11 insiders sit on the buying side and 1 insider on the selling side. No amount is published for 30 filings, which the totals therefore leave out. Open-market purchases are the filings investors watch most closely, because the insider pays for the shares out of pocket. Among those who bought: 6 senior executives and 5 board members. The largest single trade was a purchase of €12k by 우석민, published on 30 April 2026, equal to 0.047% of the market capitalisation.
The clock since the last published purchase (9 November 2026) now reads 0 days. Typically, a trade is published a median of 1 day after it takes place. That lag is the time during which only the insider knows about the trade.
For context, the typical company on the same exchange (median of 2,657 companies) published 7 filings over the same period, against 32 filings here. Since 2021, the database holds 73 purchases and 1 sale by insiders of the company.
In the same sector, recent insider purchases at Dynavox Group AB and Vetoquinol SA also feature in our signals. This summary is built from DART (FSS) disclosures alone and does not predict where the share price will go.
Who traded when
BuySale+4 other insiders
Since the insiders bought
- -37.8%Entry ₩1,776 · Close 06 Nov 2026 ₩1,104
- -37.8%Entry ₩1,776 · Close 06 Nov 2026 ₩1,104
- -37.8%Entry ₩1,776 · Close 06 Nov 2026 ₩1,104
Entry is the close on the day after publication, the first price a reader could act on. Prices in the listing currency. Past moves are not a forecast.
This score ranks the purchase within its own market. A position size is suggested only on the venues of the backtested strategy universe; elsewhere, signals stay on watch. Not investment advice.
Transparent value + quality ranking, distinct from the insider signal.
Financial data
as of FY 2025FY ended December 2025 · cache
- 6,000 sharesShareKRXDART:20261109000016Canonical exit: 7 Feb 2027 (T+90)
- 3,203 sharesShareKRXDART:20261109000013Canonical exit: 7 Feb 2027 (T+90)
- 33,000 sharesShareKRXDART:20261102000016Canonical exit: 31 Jan 2027 (T+90)
- 3,351 sharesShareKRXDART:20261027000023Canonical exit: 25 Jan 2027 (T+90)
- 7,000 sharesShareKRXDART:20261027000021Canonical exit: 25 Jan 2027 (T+90)
- Other0DART
- Other0DART
- Other0DART
- 3,000 sharesShareKRXDART:20261006000035Canonical exit: 4 Jan 2027 (T+90)
- Other0DART
- Other0DART
- Other0DART
- Other0DART
- 3,638 sharesShareKRXDART:20260812000137Canonical exit: 10 Nov 2026 (T+90)
- 2,466 sharesShareKRXDART:20260805000103Canonical exit: 3 Nov 2026 (T+90)
- 2,779 sharesShareKRXDART:20260805000115Canonical exit: 3 Nov 2026 (T+90)
- 8,480 sharesShareKRXDART:20260702000045Canonical exit: 30 Sept 2026 (T+90)
- 119,000 sharesShareKRXDART:20260702000043
- 5,365 sharesShareKRXDART:20260611000194Canonical exit: 9 Sept 2026 (T+90)
- 11,184 shares0.047% mcap100.0% of flowKRXDART:20260430000394Canonical exit: 27 Jul 2026 (T+90)
- 2,702 sharesShareKRXDART:20260430000104Canonical exit: 27 Jul 2026 (T+90)
- 2,702 sharesShareKRXDART:20260430000426Canonical exit: 27 Jul 2026 (T+90)
- 7,409 sharesShareKRXDART:20260430000081Canonical exit: 27 Jul 2026 (T+90)
- 2,824 sharesShareKRXDART:20260429000532Canonical exit: 27 Jul 2026 (T+90)
- 2,534 sharesShareKRXDART:20260429000321Canonical exit: 27 Jul 2026 (T+90)
25 of 96 declarations
About MYUNGMOON Pharm co.,Ltd
명문제약 is a healthcare and pharmaceutical company listed on the XKRX. It specializes in the development and manufacturing of pharmaceutical products.
Recent ranked signals in the same sector
Purchases our model currently ranks for the recommendations list.
All recommendations
